在表皮生长因子受体 (EGFR) 突变的晚期或转移性非小细胞肺癌参与者中,皮下注射阿米万他单抗与静脉注射阿米万他单抗相比,拉泽替尼的研究 (PALOMA-3)
在接受奥希替尼和化疗后进展的 EGFR 突变晚期或转移性非小细胞肺癌患者中,一项 3 期、开放标签、随机研究 Lazertinib 联合皮下注射 Amivantamab 与静脉注射 Amivantamab 进行比较
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 第三阶段
扩展访问
联系人和位置
学习地点
-
-
-
Beijing、中国、100191
- Peking University Third Hospital
-
Beijing、中国、100050
- Beijing Friendship Hospital Capital Medical University
-
Beijing、中国、100038
- Beijing Shijitan Hospital, Capital Medical University
-
Beijing、中国、200240
- Cancer Hospital Chinese Academy of Medical Sciences
-
Beijing、中国、101149
- Beijing Chest hospital, Capital medical university
-
Changchun、中国、130012
- Jilin cancer hospital
-
Changzhou、中国、213004
- The First People's Hospital Of Changzhou
-
Chengdu、中国、610041
- Sichuan Cancer Hospital
-
Chengdu、中国、610047
- West China Hospital Sichuan University
-
Chongqing、中国、400030
- Chongqing University Cancer Hospital
-
Chongqing、中国、400038
- Southwest Hospital
-
Ganzhou、中国、341000
- First Affiliated Hospital of Gannan Medical University
-
Guangzhou、中国、510080
- The First Affiliated Hospital Sun Yat sen University
-
Guangzhou、中国、510000
- Sun Yat-Sen Memorial Hospital Sun Yat-sen University
-
Hangzhou、中国、310022
- Zhejiang Cancer Hospital
-
Hangzhou、中国、310009
- The Second Affiliated Hospital of Zhejiang University College of Medicine
-
Hangzhou、中国、310016
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Harbin、中国、150081
- Harbin medical university cancer hospital
-
Huizhou、中国、516001
- Huizhou Municipal Central Hospital
-
Huizhou、中国、516003
- Huizhou First Hospital
-
Liuzhou、中国、545026
- Liuzhou people's Hospital
-
Nanchong、中国、637100
- Affiliated Hospital of North Sichuan Medical College
-
Shanghai、中国、200032
- Fudan University Shanghai Cancer Center
-
Shenyang、中国、110004
- Shengjing Hospital Of China Medical University
-
Shenzhen、中国、518055
- Shenzhen university General Hospital
-
Shenzhen、中国、518001
- Shenzhen People s Hospital
-
Tianjin、中国、300060
- Tianjin Medical University Cancer Institute and Hospital
-
Wuhan、中国、430022
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology
-
Xi'an、中国、710061
- The First Affiliated Hospital of Xian Jiaotong University
-
Xiangyang、中国、441021
- Xiangyang Central Hospital
-
Yantai、中国、264000
- Yantai Yuhuangding Hospital
-
Zhengzhou、中国、450008
- Henan Cancer Hospital
-
-
-
-
-
Haifa、以色列、3109601
- Rambam Medical Center
-
Kfar Saba、以色列、44281
- Meir Medical Center
-
Petah Tikva、以色列、49100
- Rabin Medical Center
-
Ramat Gan、以色列、5262100
- Chaim Sheba Medical Center
-
Yeruham、以色列、91031
- Shaare Zedek Medical Center
-
-
-
-
Ontario
-
Ottawa、Ontario、加拿大、K1H 8L6
- The Ottawa Hospital Cancer Centre
-
Toronto、Ontario、加拿大、M5G 1Z5
- Princess Margaret Hospital
-
-
-
-
-
Changhua、台湾、50006
- Changhua Christian Hospital
-
Kaohsiung City、台湾、833
- Chang Kung Memorial Hospital
-
Kaohsiung City、台湾、80756
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung、台湾、403
- Chung Shan Medical University Hospital
-
Tainan、台湾、70403
- National Cheng Kung University Hospital
-
Taipei、台湾、10048
- National Taiwan University Hospital
-
Taipei、台湾、106
- National Taiwan University Cancer Center
-
Taoyuan、台湾、33382
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Adana、土耳其(türkiye)、01060
- Adana City Hospital
-
Adana、土耳其(türkiye)、01120
- Adana Baskent Hospital
-
Ankara、土耳其(türkiye)、06800
- Ankara Bilkent City Hospital
-
Ankara、土耳其(türkiye)、06520
- Memorial Ankara Hastanesi
-
Ankara、土耳其(türkiye)、06560
- Gazi University Hospital
-
Edirne、土耳其(türkiye)、22030
- Trakya University Medical Faculty
-
Istanbul、土耳其(türkiye)、34098
- Istanbul University Cerrahpasa Medical Faculty
-
Istanbul、土耳其(türkiye)、34457
- Acıbadem Maslak Hospital
-
Izmir、土耳其(türkiye)、35330
- Dokuz Eylul University Medical Faculty
-
Izmir、土耳其(türkiye)、35575
- IEU Medical Point Hospital
-
Samsun、土耳其(türkiye)、55200
- Medical Park Samsun Hastanesi
-
-
-
-
-
Barretos、巴西、14784-400
- Fundacao Pio XII
-
Belo Horizonte、巴西、30110-017
- Cetus Oncologia
-
Curitiba、巴西、80810-050
- Instituto Cionc de Ensino e Pesquisa S/S
-
Florianópolis、巴西、88020-210
- Ynova Pesquisa Clinica
-
Ipatinga、巴西、35162 189
- Fundacao Sao Francisco Xavier HMC Unidade de Oncologia
-
Pelotas、巴西、96020 080
- UPCO Unidade de Pesquisa Clinica em Oncologia
-
Porto Alegre、巴西、90610-000
- Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
-
Rio de Janeiro、巴西、22061-080
- Impar Servicos Hospitalares S/A
-
Rio de Janeiro、巴西、22250 905
- Oncoclinicas Rio de Janeiro S A
-
Rio de Janeiro、巴西、22281 100
- Instituto D Or de Pesquisa e Ensino IDOR
-
Salvador、巴西、40170 110
- Nucleo de Oncologia da Bahia
-
Santo André、巴西、09060-650
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo、巴西、04014-002
- Núcleo de Pesquisa São Camilo
-
São Paulo、巴西、04543-000
- Onco Star SP Oncologia Ltda
-
São Paulo、巴西、05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo、巴西、01409-002
- Impar Servicos Hospitalares SA Hospital Nove de Julho
-
-
-
-
-
Berlin、德国、13125
- Evangelische Lungenklinik Berlin
-
Georgsmarienhütte、德国、49124
- Niels-Stensen-Kliniken Franziskus-Hospital Harderberg
-
Giessen、德国、35392
- Universitaetsklinikum Giessen und Marburg GmbH
-
Münster、德国、48149
- Munster University Hospital
-
Recklinghausen、德国、45659
- Oncologianova GmbH
-
Weinsberg、德国、74189
- Onkologische Schwerpunktpraxis
-
-
-
-
-
Bari、意大利、70124
- Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II
-
Bologna、意大利、40138
- A O U Sant Orsola Malpighi
-
Milan、意大利、20141
- European Institute of Oncology
-
Orbassano、意大利、10043
- Aou San Luigi Gonzaga
-
Padova、意大利、35128
- Istituto Oncologico Veneto - IRCCS
-
Ravenna、意大利、48121
- Ospedale S. Maria Delle Croci
-
Roma、意大利、00152
- A.O. San Camillo Forlanini
-
Rome、意大利、00144
- Istituto Nazionale Tumori Regina Elena
-
Rozzano、意大利、20089
- Istituto Clinico Humanitas
-
-
-
-
-
Chūōku、日本、104 0045
- National Cancer Center Hospital
-
Himeji、日本、670-8520
- National Hospital Organization Himeji Medical Center
-
Hirakata、日本、573 1191
- Kansai Medical University Hospital
-
Kanagawa、日本、241-8515
- Kanagawa Cancer Center
-
Kurashiki、日本、710-8602
- Kurashiki Central Hospital
-
Kurume、日本、830-0011
- Kurume University Hospital
-
Matsusaka、日本、515-8544
- Matsusaka Municipal Hospital
-
Niigata、日本、951-8566
- Niigata Cancer Center Hospital
-
Okayama、日本、700 8558
- Okayama University Hospital
-
Osaka、日本、541 8567
- Osaka International Cancer Institute
-
Sapporo、日本、060-8648
- Hokkaido University Hospital
-
Shizuoka、日本、411 8777
- Shizuoka Cancer Center
-
Tokyo、日本、135 8550
- The Cancer Institute Hospital of JFCR
-
Toyoake、日本、470-1192
- Fujita Health University Hospital
-
Toyonaka-shi、日本、560-8552
- National Hospital Organization Osaka Toneyama Medical Center
-
Wakayama、日本、641 8510
- Wakayama Medical University Hospital
-
Yamaguchi、日本、740-8510
- National Hospital Organization Iwakuni Clinical Center
-
Yamaguchi、日本、755-0241
- National Hospital Organization Yamaguchi Ube Medical Center
-
-
-
-
-
La Tronche、法国、38700
- CHU Grenoble
-
Lille、法国、59000
- Institute Coeur Poumon
-
Limoges、法国、87000
- CHU de Limoges Hopital Dupuytren
-
Marseille、法国、13915
- Hopital Nord
-
-
-
-
-
Bydgoszcz、波兰、85 796
- Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
-
Krakow、波兰、31-202
- Krakowski Szpital Specjalityczny im. Jana Pawla II
-
Otwock、波兰、05 400
- Mazowieckie Centrum Leczenia Chorob Pluc
-
Poznan、波兰、60-693
- Private Specialist Hospitals - MedPolonia
-
Warsaw、波兰、02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
-
-
-
-
Bangkok、泰国、10700
- Siriraj Hospital
-
Bangkok、泰国、10400
- Phramongkutklao Hospital and Medical College
-
Chiang Mai、泰国、50200
- Chiang Mai University
-
-
-
-
-
Adelaide、澳大利亚、5000
- Cancer Research SA
-
Camperdown、澳大利亚、2050
- Chris O'Brien Lifehouse
-
Melbourne、澳大利亚、3000
- Peter MacCallum Cancer Centre
-
Murdoch、澳大利亚、6150
- St John of God Hospital Murdoch
-
Westmead、澳大利亚、2145
- Westmead Hospital
-
Woolloongabba、澳大利亚、4102
- Princess Alexandra Hospital
-
-
-
-
California
-
Duarte、California、美国、91010
- City of Hope Duarte
-
Irvine、California、美国、92618
- City of Hope Orange County Lennar Foundation Cancer Center
-
Long Beach、California、美国、90813
- City of Hope Long Beach Elm
-
-
Colorado
-
Denver、Colorado、美国、80206
- National Jewish Health
-
-
Florida
-
Boca Raton、Florida、美国、33486
- Baptist Lynn Cancer Institute
-
Orlando、Florida、美国、32806
- Orlando Health
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- University of Kansas
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816
- Astera Cancer Care
-
New Brunswick、New Jersey、美国、08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York、New York、美国、10016
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center
-
The Bronx、New York、美国、10461
- Montefiore Medical Center
-
-
Oregon
-
Portland、Oregon、美国、97213
- Providence Portland Medical Center
-
Portland、Oregon、美国、97225
- Providence Oncology and Hematology Care Clinic Westside
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- Medical University of South Carolina
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- Virginia Cancer Specialists
-
-
-
-
-
Birmingham、英国、B9 5SS
- Birmingham Heartlands Hospital
-
London、英国、W2 1NY
- Imperial College Healthcare
-
Newcastle upon Tyne、英国、NE7 7DN
- Newcastle Freeman Hospital
-
Sutton、英国、SM2 5PT
- Royal Marsden Hospital
-
-
-
-
-
Braga、葡萄牙、4710-243
- Hospital de Braga
-
Lisbon、葡萄牙、1500-650
- Hospital da Luz, SA
-
Lisbon、葡萄牙、1998-018
- Hosp. Cuf Descobertas
-
Senhora da Hora、葡萄牙、4464-513
- Ulsm - Hosp. Pedro Hispano
-
-
-
-
-
A Coruña、西班牙、15006
- Hosp Univ A Coruna
-
Alicante、西班牙、03010
- Hosp. Gral. Univ. de Alicante
-
Barcelona、西班牙、8028
- Hosp. Univ. Quiron Dexeus
-
Barcelona、西班牙、08036
- Hosp Clinic de Barcelona
-
Barcelona、西班牙、08035
- Hosp Univ Vall D Hebron
-
Córdoba、西班牙、14004
- Hosp Reina Sofia
-
Las Palmas de Gran Canaria、西班牙、35016
- Hosp. Univ. Insular de Gran Canaria
-
Lugo、西班牙、27003
- Hosp. Univ. Lucus Augusti
-
Madrid、西班牙、28046
- Hosp. Univ. La Paz
-
Madrid、西班牙、28009
- Hosp. Gral. Univ. Gregorio Maranon
-
Majadahonda、西班牙、28222
- Hosp. Univ. Pta. de Hierro Majadahonda
-
Málaga、西班牙、29011
- Hosp Regional Univ de Malaga
-
Oviedo、西班牙、33011
- Hosp. Univ. Central de Asturias
-
Palma de Mallorca、西班牙、07120
- Hosp. Univ. Son Espases
-
Seville、西班牙、41013
- Hosp. Virgen Del Rocio
-
Valencia、西班牙、46026
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Buenos Aires、阿根廷、1431
- CEMIC (Centro de Educación Médica e Investigaciones Clínicas)
-
CABA、阿根廷、C1122
- IADT Instituto Argentino de Diagnostico y Tratamiento
-
Chabas、阿根廷、C1425
- Centro Oncológico Korben
-
Córdoba、阿根廷、5000
- Sanatorio Allende
-
Córdoba、阿根廷、5000
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Viedma、阿根廷、R8500ACE
- Clínica Viedma
-
-
-
-
-
Gyeonggi-do、韩国、13496
- CHA Bundang Medical Center, CHA University
-
Gyeonggi-do、韩国、10408
- National Cancer Center
-
Gyeongsangnam-do、韩国、52727
- GyeongSang National University Hospital
-
Jeollanam-do、韩国、58128
- Chonnam National University Hwasun Hospital
-
Seongnam-si、韩国、13620
- Seoul National University Bundang Hospital
-
Seoul、韩国、03080
- Seoul National University Hospital
-
Seoul、韩国、05505
- Asan Medical Center
-
Seoul、韩国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韩国、06351
- Samsung Medical Center
-
-
-
-
-
Kuala Lumpur、马来西亚、59100
- University Malaya Medical Centre
-
Kuala Lumpur、马来西亚、50450
- Prince Court Medical Centre
-
Kuala Lumpur、马来西亚、59100
- Pantai Hospital Kuala Lumpur
-
Kuching、马来西亚、93586
- Hospital Umum Sarawak
-
Petaling Jaya、马来西亚、46050
- Beacon Hospital Sdn Bhd
-
Petaling Jaya、马来西亚、47500
- Sunway Medical Centre
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Have histologically or cytologically confirmed, advanced or metastatic non-small cell lung cancer (NSCLC), characterized by either epidermal growth factor receptor (EGFR) Exon 19 deletion (Exon 19del) or Exon 21 leucine 858 to arginine substitution (Exon 21 L858R) mutation by an Food and Drug Administration (FDA)-approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United Started [US]) or an accredited local laboratory (sites outside of the US)
- Have progressed on or after osimertinib (or another approved 3rd generation epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [TKI]) and platinum-based chemotherapy (irrespective of order). a) The 3rd generation EGFR TKI must have been administered as the first EGFR TKI for metastatic disease or as the second TKI after prior treatment with first- or second-generation EGFR TKI in participants with metastatic EGFR T790M mutation positive NSCLC. b) Participants who decline or are otherwise ineligible for chemotherapy may be enrolled after discussion with the medical monitor. c) Any adjuvant or neoadjuvant treatment, whether with a 3rd generation EGFR TKI or platinum based chemotherapy, would count towards the prior treatment requirement if the participant experienced disease
- Have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) version 1.1
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
- Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade less than or equal to (<=) 2 peripheral neuropathy, and Grade <=2 hypothyroidism stable on hormone replacement)
Exclusion Criteria:
- Participant has received cytotoxic, investigational, or targeted therapies beyond one regimen of platinum-based chemotherapy and EGFR inhibitors
- Participant has received radiotherapy for palliative purposes less than 7 days prior to randomization
- Participant has symptomatic or progressive brain metastases
- Participant has leptomeningeal disease, or participant has spinal cord compression not definitively treated with surgery or radiation
- Participant has uncontrolled tumor-related pain
- Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: Lazertinib with Amivantamab SC-CF
Lazertinib 240 milligrams (mg) will be administered orally once daily. Participants will receive amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 mg/ 2240 mg depending on the body weight by manual injection. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the long-term extension (LTE) Phase. |
Lazertinib tablets will be administered orally.
其他名称:
Amivantamab injection will be administered subcutaneously by manual injection.
其他名称:
|
|
实验性的:Arm B: Lazertinib with Amivantamab Intravenous (IV) Infusion
Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the LTE Phase. |
Lazertinib tablets will be administered orally.
其他名称:
Amivantamab will be administered by IV infusion.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State
大体时间:Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)
|
Ctrough was the observed serum concentration of Amivantamab at steady state immediately prior to the next drug administration. |
Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)
|
|
For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab
大体时间:Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)
|
Ctrough was the observed serum concentration of Amivantamab immediately prior to the next drug administration. |
Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)
|
|
Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2
大体时间:Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1
|
AUC (Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15 were reported. |
Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
客观缓解率(ORR)
大体时间:最长 3 年 4 个月
|
最长 3 年 4 个月
|
|
无进展生存期 (PFS)
大体时间:最长可达 3 年 4 个月
|
最长可达 3 年 4 个月
|
|
缓解持续时间(DOR)
大体时间:最长3年4个月
|
最长3年4个月
|
|
反应时间 (TTR)
大体时间:长达3年4个月
|
长达3年4个月
|
|
出现不良事件(AEs)的参与者数量
大体时间:长达 3 年 4 个月
|
长达 3 年 4 个月
|
|
按严重程度分类的不良事件参与者人数
大体时间:最长3年4个月
|
最长3年4个月
|
|
出现临床实验室异常的参与者人数
大体时间:长达3年4个月
|
长达3年4个月
|
|
按严重程度划分出现临床实验室检查异常结果的参与者人数
大体时间:长达3年4个月
|
长达3年4个月
|
|
发生输注相关反应(IRRs)的参与者人数
大体时间:最长3年4个月
|
最长3年4个月
|
|
按严重程度划分发生IRR的参与者人数
大体时间:最长3年4个月
|
最长3年4个月
|
|
对于欧盟及其他接受周期 2 第 1 天方案的所有区域:周期 2 第 1 天给药前观察到的阿米万他单抗血清浓度(谷浓度)
大体时间:第2周期第1天给药前(每个周期为28天)
|
第2周期第1天给药前(每个周期为28天)
|
|
对于欧盟及任何适用地区:稳态下第4周期第1日观察到的Amivantamab血清谷浓度(Ctrough)
大体时间:第4周期第1天给药前(每个周期为28天)
|
第4周期第1天给药前(每个周期为28天)
|
|
模型预测的Amivantamab稳态浓度时间曲线下面积(第1天至第15天)(AUC [第1-15天])第4周期
大体时间:周期4:A组:第1天给药前、给药后24、48、72、96、168和360小时;B组:第1天输注前、输注结束+10分钟、输注结束+2小时、输注结束+6小时、输注结束+24小时、输注结束+48小时、输注结束+72小时、输注结束+168小时和输注结束+360小时
|
周期4:A组:第1天给药前、给药后24、48、72、96、168和360小时;B组:第1天输注前、输注结束+10分钟、输注结束+2小时、输注结束+6小时、输注结束+24小时、输注结束+48小时、输注结束+72小时、输注结束+168小时和输注结束+360小时
|
|
存在抗阿米万他单抗抗体和抗rHuPH20抗体的参与者百分比
大体时间:最长3年4个月
|
最长3年4个月
|
|
通过治疗管理满意度问卷(TASQ)评估的癌症治疗满意度参与者百分比
大体时间:最长3年4个月
|
最长3年4个月
|
|
随时间评估的治疗管理满意度问卷(TASQ)相对于基线的变化
大体时间:从基线(第1天,第1周期)至3年4个月(每周期28天)
|
从基线(第1天,第1周期)至3年4个月(每周期28天)
|
|
参与者就座时间
大体时间:最长3年4个月
|
最长3年4个月
|
|
参与者在治疗室的停留时间
大体时间:最长3年4个月
|
最长3年4个月
|
|
治疗持续时间
大体时间:最长3年零4个月
|
最长3年零4个月
|
|
药物配制、治疗实施及治疗后监测的活跃医疗保健专业人员(HCP)时间
大体时间:长达3年4个月
|
长达3年4个月
|
合作者和调查者
调查人员
- 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物和有用的链接
一般刊物
- Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massuti B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Sendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A; PALOMA-3 Investigators. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10.
- Leighl NB, Passaro A, Akamatsu H, Spira AI, Nguyen D, Qin A, Schuchard J, Gamil M, Baig M, Alexander M. Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer. Future Oncol. 2026 Aug 24:1-17. doi: 10.1080/14796694.2026.2709936. Online ahead of print.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CR109211
- 2022-000525-25 (EudraCT编号)
- 61186372NSC3004 (其他标识符:Janssen Research & Development, LLC)
- 2024-512045-16-00 (注册表标识符:EUCT number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.